Frankfurt
26.11.25 | 08:03
0,145 Euro
-35,56 % -0,080
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 11.11. | AlzeCure Pharma: AlzeCure Publishes its Interim Report for January - September 2025 | 198 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / November 11, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - AlzeCure Pharma AB (publ) (FN STO:ALZCUR) today announced that its interim report for the period January... ► Artikel lesen | |
| 14.10. | AlzeCure Pharma: Response Letter to Previous Article Published about Alzstatin's Unique Mode of Action Against Alzheimer's | 516 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / October 14, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR)(STO:ALZCUR)(FRA:AC6), a pharmaceutical company that develops candidate drugs for diseases affecting the... ► Artikel lesen | |
| ALZECURE PHARMA Aktie jetzt für 0€ handeln | |||||
| 08.09. | AlzeCure Pharma: Positive Study Results with TrkA-NAM ACD137 Against Knee Osteoarthritis Presented at Pain Conference NeuPSIG 2025 | 260 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / September 8, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing... ► Artikel lesen | |
| 04.09. | AlzeCure Pharma: Data from AlzeCure's Pain Project ACD440 Presented at the NeuPSIG 2025 Pain Conference | 296 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / September 4, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing... ► Artikel lesen | |
| 26.08. | AlzeCure Pharma: AlzeCure Publishes its Interim Report for January - June 2025 | 325 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / August 26, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR) today announced that its interim report for the period January - June 2025 is now available on the company's... ► Artikel lesen | |
| 20.08. | AlzeCure Pharma: AlzeCure Appoints Cecilia Wadell as New Head of Development | 371 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / August 20, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing... ► Artikel lesen | |
| 19.08. | AlzeCure Pharma Livestreams Event about The Pain Project ACD440 and The Opportunities Within Orphan Drugs | 343 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / August 19, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing... ► Artikel lesen | |
| 11.08. | New last trading day for paid subscription shares (BTA) of AlzeCure Pharma AB | 231 | GlobeNewswire | At the request of AlzeCure Pharma AB, the last trading day in AlzeCure Pharma AB's paid subscription shares will be changed from 2025-08-14 to 2025-08-13.
Instrument:
Paid subscription... ► Artikel lesen | |
| 05.08. | AlzeCure Pharma: New Scientific Data with TrkA-NAM ACD137 Against Knee Osteoarthritis to be Presented at Pain Conference | 397 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / August 5, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing... ► Artikel lesen | |
| 29.07. | AlzeCure Pharma: New Scientific Article Published on Positive Clinical Results with Painless ACD440 Against Neuropathic Pain | 473 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / July 29, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing... ► Artikel lesen | |
| 24.07. | AlzeCure Pharma: AlzeCure's Rights Issue Oversubscribed, And the Company Resolves on A Directed Share Issue Under the Framework of An Overallotment Option | 355 | ACCESS Newswire | THIS PRESS RELEASE MAY NOT BE PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY IN OR INTO AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, THE UNITED STATES, BELARUS, RUSSIA... ► Artikel lesen | |
| 23.07. | AlzeCure Pharma: AlzeCure's Rights Issue Oversubscribed According to Preliminary Results | 310 | ACCESS Newswire | THIS PRESS RELEASE MAY NOT BE PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY IN OR INTO AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, THE UNITED STATES, BELARUS, RUSSIA... ► Artikel lesen | |
| 21.07. | AlzeCure Pharma: AlzeCure Presents ACD440 at the NeuPSIG 2025 Pain Conference | 338 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / July 21, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing... ► Artikel lesen | |
| 16.07. | FDA grants orphan status for AlzeCure's pain drug candidate | 3 | Pharmaceutical Business Review | ||
| 16.07. | AlzeCure Pharma: AlzeCure Receives Additional Subscription Commitments of Approximately SEK 7 million in the Ongoing Rights Issue | 306 | ACCESS Newswire | NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, WITHIN OR INTO THE AUSTRALIA, HONGKONG, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, THE UNITED STATES... ► Artikel lesen | |
| 15.07. | AlzeCure Pharma: AlzeCure's Pain Project ACD440 Granted Orphan Drug Status in the US by the FDA | 359 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / July 15, 2025 / AlzeCure Pharma (STO:ALZCUR) (FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases... ► Artikel lesen | |
| 02.07. | The Extraordinary General Meeting of AlzeCure Pharma AB Approved the Decision on the New Issue of Shares | 383 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / July 2, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - At an extraordinary general meeting in AlzeCure Pharma AB on July 2, 2025, the shareholders decided to approve... ► Artikel lesen | |
| 02.07. | XFRA CAPITAL ADJUSTMENT INFORMATION - 02.07.2025 | 360 | Xetra Newsboard | Das Instrument 3MM FR0013296746 ADVICENNE (PROM.) EO-,20 EQUITY wird ex Kapitalmassnahme gehandelt am 02.07.2025 The instrument 3MM FR0013296746 ADVICENNE (PROM.) EO-,20 EQUITY is traded ex capital... ► Artikel lesen | |
| 17.06. | AlzeCure Pharma: AlzeCure Receives an Additional Subscription Commitment of Approximately SEK 5 million in the Upcoming Rights Issue | 380 | ACCESS Newswire | NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, WITHIN OR INTO THE RUSSIAN FEDERATION, BELARUS, AUSTRALIA, HONGKONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND... ► Artikel lesen | |
| 16.06. | Notice To Extraordinary General Meeting In Alzecure Pharma AB | 366 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / June 16, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - The shareholders of AlzeCure Pharma AB are hereby summoned to an extraordinary general meeting to be held on... ► Artikel lesen |
1 2 Weiter >>
37 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VERTEX PHARMACEUTICALS | 371,15 | -0,11 % | VERTEX PHARMACEUTICALS INC stürzt ab - Alarmstufe Rot! | ||
| VIATRIS | 9,176 | +0,02 % | EQS-News: Viatris Inc.: Europäische Studie zeigt sinkende Preise, steigende Kosten und Engpässe - Ergebnisse einer unabhängigen Studie, die während der World AMR Awareness Week von Viatris und Medicines for Europe vorgestellt ... | EQS-News: Viatris Inc.
/ Schlagwort(e): Sonstiges/Sonstiges
Europäische Studie zeigt sinkende Preise, steigende Kosten und Engpässe - Ergebnisse einer unabhängigen Studie, die... ► Artikel lesen | |
| ALTIMMUNE | 4,518 | +1,76 % | Jefferies Konferenz: Altimmune skizziert Zukunft des Lebermedikaments Pemvidutid | ||
| OPKO HEALTH | 1,152 | -1,01 % | JPMorgan initiates Opko Health stock with Neutral rating | ||
| JAGUAR HEALTH | 1,300 | +4,84 % | Morning Market Movers: Foxx Development Holdings, Jaguar Health, Mawson Infrastructure Group, Mingteng International See Big Swings | CANBERA (dpa-AFX) - At 6:45 a.m. ET on Tuesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 1,300 | +4,00 % | SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Announces Independent Data Monitoring Committee Periodic Review and Positive Recommendation to Continue Pivotal Phase 3 REGAL Trial of GPS in AML Without Modification | - Final Analysis Anticipated by Year-End Upon Occurrence of 80 Events - NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS'' or the... ► Artikel lesen | |
| AURINIA PHARMACEUTICALS | 14,140 | +0,39 % | Jefferies upgrades Aurinia Pharmaceuticals stock to Buy on strong Lupkynis sales | ||
| KIORA PHARMACEUTICALS | 1,800 | +0,56 % | Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals Reports Third Quarter 2025 Results; Company Advances Pipeline with Two Actively Enrolling Phase 2 Clinical Trials for Retinal Diseases | Encinitas, California--(Newsfile Corp. - November 7, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced third quarter 2025 financial results and provided... ► Artikel lesen | |
| LIPOCINE | 3,270 | 0,00 % | Lipocine Inc.: Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) | Per the Drug Safety Monitoring Board (DSMB) meeting evaluating one-third of planned participants, study to continue as planned
More than half of planned participants... ► Artikel lesen | |
| ACLARIS THERAPEUTICS | 2,396 | +1,65 % | Aclaris Therapeutics, Inc.: Aclaris Therapeutics Announces Late-Breaking Abstract and Oral Presentation On ATI-2138 Phase 2a Results at the 2025 European Academy of Dermatology and Venereology (EADV) Congress | - Late Breaking Abstract to Present Additional Data from Aclaris' Phase 2a Trial of ATI-2138 in Atopic Dermatitis- WAYNE, Pa., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:... ► Artikel lesen | |
| PHOTOCURE | 5,100 | +3,03 % | Photocure: New budget impact model study in 4 European countries concludes that BLC use offers a clinically meaningful and economically rational approach to NMIBC management | OSLO, Norway , Nov. 19, 2025 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces the publication of the study "Hexaminolevulinate-enhanced photodynamic... ► Artikel lesen | |
| EUROBIO SCIENTIFIC | 24,450 | 0,00 % | ABL Diagnostics Appoints Eurobio Scientific as Exclusive Distributor for Its VELA Product Line in a Targeted Segment of the French Market | Regulatory News:
ABL Diagnostics (Euronext Paris: ABLD), a French company specializing in advanced molecular diagnostics, announces the signing of an exclusive distribution agreement with Eurobio... ► Artikel lesen | |
| MEDICURE | 0,620 | 0,00 % | Medicure, Inc.: Medicure Reports Financial Results for Quarter Ended September 30, 2025 | WINNIPEG, MB / ACCESS Newswire / November 19, 2025 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC:MCUJF), a company focused on the development and commercialization of pharmaceuticals... ► Artikel lesen | |
| BAYER | 30,455 | -1,22 % | Bayer: Nächste Zulassung - Aktie abverkauft | Einmal mehr ist es der Bayer-Aktie nicht gelungen, die Widerstandszone bei der Marke von 30,00 Euro zu überwinden. Zwischen 27,00 und 27,50 Euro kann sich der DAX-Wert wieder stabilisieren. Unterstützend... ► Artikel lesen | |
| NOVO NORDISK | 41,855 | +3,28 % | Der Wettbewerb um Abnehmmedikamente spitzt sich zu und Novo Nordisk greift nun über den Preis an | Es ist schon eine Weile her, dass Novo Nordisk die eigenen Anleger mit Erfolgsmeldungen in Ekstase versetzen konnte. Große Enttäuschung verursachte der Konzern hingegen bereits vor knapp einem Jahr... ► Artikel lesen |
ALZECURE PHARMA AB gehört der Branche Pharma an. Mit einer aktuellen Kursveränderung von -0,080 (-35,56 %) liegt der Kurs bei 0,145 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ALZECURE PHARMA AB finden Sie auf Wallstreet Online.